{"id":"mt-7117-high-dose","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Dyspepsia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"MT-7117 directly activates soluble guanylate cyclase, an enzyme that produces cyclic guanosine monophosphate (cGMP), a key signaling molecule in vascular smooth muscle relaxation. By increasing cGMP levels, the drug promotes vasodilation and reduces pulmonary vascular resistance, making it potentially beneficial for pulmonary hypertension. This mechanism differs from phosphodiesterase-5 inhibitors, which prevent cGMP breakdown rather than stimulating its production.","oneSentence":"MT-7117 is a selective activator of the soluble guanylate cyclase (sGC) pathway that increases intracellular cGMP levels to promote vasodilation and reduce pulmonary vascular resistance.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:22:18.186Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pulmonary arterial hypertension (PAH)"}]},"trialDetails":[{"nctId":"NCT03520036","phase":"PHASE2","title":"Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria","status":"COMPLETED","sponsor":"Tanabe Pharma America, Inc.","startDate":"2018-07-05","conditions":"Erythropoietic Protoporphyria (EPP)","enrollment":102},{"nctId":"NCT04402489","phase":"PHASE3","title":"Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria or X-Linked Protoporphyria","status":"COMPLETED","sponsor":"Tanabe Pharma America, Inc.","startDate":"2020-06-01","conditions":"EPP, XLP","enrollment":184}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Dersimelagon"],"phase":"phase_3","status":"active","brandName":"MT-7117 high dose","genericName":"MT-7117 high dose","companyName":"Tanabe Pharma America, Inc.","companyId":"tanabe-pharma-america-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MT-7117 is a selective activator of the soluble guanylate cyclase (sGC) pathway that increases intracellular cGMP levels to promote vasodilation and reduce pulmonary vascular resistance. Used for Pulmonary arterial hypertension (PAH).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}